Suresh Sivanesan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suresh Sivanesan has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Aysha Al-Ani
Department of Gastroenterology The Royal Melbourne Hospital Melbourne Victoria Australia
29 shared publications - Alex Boussioutas
Peter MacCallum Cancer Centre
28 shared publications - Allan D. Spigelman
16Faculty of Medicine, University of New South Wales, Sydney, Australia
28 shared publications - Arun Gupta
12Honorary Research Fellow, Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, Melbourne, Australia
28 shared publications - Brooke E. Flanders
National Study Co-ordinator, Department of Colorectal Medicine and Genetics, Royal Melbourne Hospital, Victoria, Australia
28 shared publications - David Williams
Head of Department of Gastroenterology and Hepatology, St Vincent’s Hospital, Sydney, Australia
28 shared publications
Latest Publications
- 27 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6814)
A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic condition caused by altered cytokine signaling, maladaptive immunity, dysbiosis, and intestinal barrier dysfunction. Although current therapies aim to correct these imbalances to induce remission, most patients ultimately relapse, suggesting that key pathogenic mechanisms persist. Here, we identified aberrant epithelial cell death signaling as an underlying feature of IBD that arises in patients in remission and on advanced therapy. Mechanistically, nascent inflammation skewed epithelial cells into an M1-macrophage–like transcriptional state that promoted RIPK1-independent necroptotic signaling. This signaling then triggered inducible nitric oxide synthase–assisted mitochondrial apoptosis of absorptive epithelial cells and PUMA-mediated intestinal stem cell death. Thus, aberrant epithelial cell death signaling represents a hallmark of IBD that occurs early in mucosal lesion development, persists despite current therapeutic strategies, and predicts clinical relapse.
- 27 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6814)
A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic condition caused by altered cytokine signaling, maladaptive immunity, dysbiosis, and intestinal barrier dysfunction. Although current therapies aim to correct these imbalances to induce remission, most patients ultimately relapse, suggesting that key pathogenic mechanisms persist. Here, we identified aberrant epithelial cell death signaling as an underlying feature of IBD that arises in patients in remission and on advanced therapy. Mechanistically, nascent inflammation skewed epithelial cells into an M1-macrophage–like transcriptional state that promoted RIPK1-independent necroptotic signaling. This signaling then triggered inducible nitric oxide synthase–assisted mitochondrial apoptosis of absorptive epithelial cells and PUMA-mediated intestinal stem cell death. Thus, aberrant epithelial cell death signaling represents a hallmark of IBD that occurs early in mucosal lesion development, persists despite current therapeutic strategies, and predicts clinical relapse.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Descriptive statistics for polyp counts of each size in the large bowel intention to treat population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Descriptive statistics for polyp counts of each size in the large bowel intention to treat population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on global polyp burden in the large bowel PP population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on global polyp burden in the large bowel PP population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 18 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Severity of adverse events by system organ class and treatment sequence
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 18 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Severity of adverse events by system organ class and treatment sequence
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on tattoo 1 polyp burden in the large bowel ITT population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on tattoo 1 polyp burden in the large bowel ITT population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 21 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Summary of protocol deviations
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 21 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Summary of protocol deviations
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Descriptive statistics for polyp counts of each size in tattoo 1 and 2 in the intention to treat population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Descriptive statistics for polyp counts of each size in tattoo 1 and 2 in the intention to treat population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on tattoo 2 polyp burden in the large bowel PP population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Ratio of mean counts for effect of treatment, week and carry-over on tattoo 2 polyp burden in the large bowel PP population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Mean difference for effects of treatment and time point on modified gastrointestinal quality of life index
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from The Effect of Butyrylated Starch on Bowel Polyps in Familial Adenomatous Polyposis: Results of a Randomized, Double-blind, Placebo-Controlled Crossover Trial
Mean difference for effects of treatment and time point on modified gastrointestinal quality of life index